
|Videos|September 10, 2019
Optimal Management of Early-Stage HCC
Advertisement
Key Takeaways:
The importance of multidisciplinary management of the underlying liver disease and function as well as the tumor burden in patients with hepatocellular carcinoma (HCC).
Solidifying interactions among locoregional practitioners, interventional radiologists, medical oncologists, and hepatologists to help define when to cease TACE (transarterial chemoembolization) and start a patient on systemic therapy.
Triggers to discontinue locoregional therapy and move to systemic therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Dr Riedell on the Long-Term Efficacy of Tisa-Cel in R/R Follicular Lymphoma
5






































